Parikshit Somani Banned for Four Years: Trimetazidine, the Food Contamination Defence and the Shadow of Valieva

There was no grandstand, no television camera, and nobody waiting for an autograph outside the fence. The August hearing took place in a room where the loudest sound was three independent tribunal judges turning pages. Across the table sat Parikshit Somani, 26, an Indian doubles player whose career-high ranking peaked at No. 256, explaining a positive test for trimetazidine collected at a lower-tier event in Astana, Kazakhstan, the previous year. His account: medication belonging to a family member had got into the food he ate. It was a very human explanation. The panel did not believe it. The International Tennis Integrity Agency (ITIA) announced that an independent tribunal banned Somani for four years, until September 2029. The panel concluded the food contamination theory was "scientifically implausible," "highly speculative" and "unconvincing." But the striking part is not the sentence. It is that the tribunal named precisely what countless files over the past decade have tried to hide: an account whose source cannot be verified is just a story, and a story defends no one. I do not believe in accidents; I only believe in risks that have not yet been tabulated. Trimetazidine is not an unfamiliar name to anyone who follows doping cases in elite sport. Pharmacologically it is a drug for stable angina. Its mechanism is not to make the heart beat harder but to make it consume less oxygen: the compound inhibits the mitochondrial enzyme 3-KAT, shifting cardiac energy metabolism away from fatty acid oxidation toward glucose oxidation. The same amount of ATP, but less oxygen. For a patient with narrowed coronary arteries, that is the difference between managing the stairs and not. On the WADA prohibited list, trimetazidine sits in class S4 — hormone and metabolic modulators — and is classified as a "non-specified substance." That classification matters more than it appears: no threshold, no grey zone, no "the level was low so we let it go." Once an accredited laboratory finds the compound, a violation file is open, and everything afterwards is only a question of sanction. Trimetazidine's plasma half-life runs at roughly seven hours in healthy adults, and most of an oral dose is excreted unchanged in urine. With a 35 mg modified-release tablet taken twice daily — the common cardiology regimen — blood concentrations reach steady state in about a day and a half. For a tennis player, this is not a muscle builder, not a recovery agent, not a hormone. It is a heart medication. That detail is exactly what makes this case harder to read than its surface suggests. One thing must be stated plainly about the body that issued the ruling. The ITIA runs professional tennis's integrity programme, tasked with investigating and prosecuting match-fixing and doping violations. The process has two layers: the agency builds the file and brings the charge, while the verdict belongs to an independent tribunal. In Somani's case, the second layer said no. Trimetazidine is the substance behind two of the biggest cases of the past decade: Kamila Valieva at the 2026 Beijing Winter Olympics, with a sample collected in December 2026, and China's swimming star Sun Yang in 2026. Valieva was banned for four years by the Court of Arbitration for Sport (CAS) in January 2026; her lawyers also argued contamination from a strawberry dessert prepared by her grandfather. Sun Yang, who tested positive for the same compound, received three months. Many look at three sanctions — three months, four years, four years — and conclude the system is arbitrary. The reality is simpler and harsher. The 2026 revision of the World Anti-Doping Code reversed the default: previously, a non-specified substance could bring two years; after 2026, the default is four years unless the athlete proves the source of contamination and no fault. Sun Yang in 2026 stood before that door. Somani and Valieva stand after it. The same compound, two different legal outcomes, only because the rules changed in between. The common thread across the three files is therefore not the trimetazidine molecule. It is the structure of the argument: a source of contamination beyond verification, told in words, leaving no physical trace. Two questions need separating here, because the public usually merges them. First: can trimetazidine enter the body through food? The scientific answer is yes, under specific conditions. The compound is water-soluble, leaches quickly from a crushed tablet, and a single 35 mg dose mixed into a meal is enough to produce a detectable urinary concentration hours later. There is nothing mysterious here. This is basic pharmacokinetics. Second: did that happen in this particular file? The tribunal's answer is that it was not proven. The three judges did not say contamination is impossible. They said this account does not stand, and they used three very heavy adjectives: scientifically implausible, highly speculative, unconvincing. The gap between those two answers is where most readers are led astray. Someone can read a headline and believe science has rejected the possibility of contamination. It has not. Science did not reject the possibility; it rejected the evidence. Data does not lie, but the body always knows how to hide its illness. Based on my experience watching matches at Challenger and ITF level in Australia, I understand why this kind of argument almost never wins at that tier. To prove contamination, the defence must do the work of a forensic unit: identify the source of the medication, sample leftover food, rebuild an hourly timeline, and show that the amount ingested matches the measured excretion. At a low-tier event, nobody keeps a family member's pharmacy records, nobody retains a portion of the meal, nobody logs what time they ate. With nothing to cross-check, there is nothing to defend. This is where I see what I always look for in an injury file: the gap between the language of data and the language of a human being. In the laboratory, there is a number. In an apartment in Astana, there is a memory of a meal. Those two do not speak the same language, and the system was never designed to translate between them. And there is a cultural detail I cannot skip when reading files like this. In many Vietnamese households, as in Central Asia, the medication of older relatives sits in the same drawer, the same plastic box, the same handbag. Sharing pills, handing medicine to a relative, storing heart tablets beside cold remedies — that is not carelessness, it is a habit formed where the nearest doctor is a three-hour drive away. In Australia, a teenage tennis player learns from the age of fourteen that every pill must pass through an anti-doping organisation's checking app before it reaches the mouth. Not because that teenager is more afraid, but because someone taught that teenager to be afraid in the right place. This is where I want to push against the usual reaction. Most commentary around the Somani case splits into two camps. One says he is guilty and four years is deserved. The other says he was roasted because he could not afford good lawyers. Both camps are arguing a question that cannot be answered: whether he intended it. But the real problem is not guilt or innocence. It is that the anti-doping system has turned "food contamination" into a template, and that template has a structural flaw: it can almost never be confirmed, and almost never be disproved. Anyone can tell that story. Very few can prove it. And when the story fails, the public assumes the storyteller is lying — when the only thing proven is that they had no records. The paradox sits here. The athlete with the fewest resources is the one most easily convicted, not because they are more likely to be contaminated, but because they are least able to rebuild a chain of evidence to defend themselves. A doubles player ranked No. 256 in Astana has no pharmacokinetics analysis team. Valieva did. She was still banned for four years. That tells us that even with full resources the door is narrow. For someone with nothing, it is nearly shut. And there is one thing both camps overlook: trimetazidine offers no clear advantage to a doubles player. It does not add power, does not speed recovery, does not make the serve faster. In an athlete with a genuine cardiac condition, it lets them train more without chest pain — but that is a medical story, not a doping story. Precisely because the edge is so faint, the substance is all the more likely to appear inadvertently: in a family medicine cabinet, in a pill someone hands you when you complain of chest pain. I have no data to assert anything about Somani's personal file. But I know one thing about measurement systems: when the cost of clearing your name exceeds the cost of serving the ban, the system no longer measures fault. It measures the ability to pay. In September 2029, Somani will turn 30. Across those four years he cannot play, cannot coach, cannot sit in the stands at any event organised by World Tennis, the WTA, the ATP, the Grand Slams or any national federation. For a doubles player once ranked No. 256 — the cohort that lives on qualifying prize money and sleeping on a training partner's floor — four years is not a break. It is the entire remainder of a career. Trimetazidine will return in other files, because it sits in the medicine cabinets of millions. The question worth asking is not whether Somani lied. The question is whether a system strict enough to default to four years can also be transparent enough to distinguish a cheat from someone who simply has no records — or whether it will keep measuring fault by account balance. People archive verdicts; I archive photographs of family medicine boxes in every apartment a young player passes through.